In addition to apatinib, the PD-1 inhibitor is another promising therapy for advanced cancer patients; this monoclonal antibody inhibits the binding between programmed death-ligand 1 (PD-L1) and PD-1, thereby promoting a T-cell-mediated anticancer effect (12). The gene discussed is PDCD1; the disease is cancer.